Abstract 20487: Hydrogel-based X-ray-visible Microspheres Development for Bariatric Arterial Embolization to Treat Obesity
Introduction: Embolization particles are used to arrest blood flow in targeted arteries, commonly to mitigate bleeding or result in ischemic tumor death. Recently, embolization particles have been introduced for bariatric arterial embolization (BAE) in preclinical and clinical setting. The objective is to suppress orexigenic hormone production, leading to weight loss. However, most commercially particle embolics are variable in size and are radiolucent, making imaging-guided interventional procedures difficult to monitor. In this study, we present the development of a hydrogel-based, imaging-visible, uniform embolic bead using Lipiodol-impregnated alginate microencapsulation system.
Methods: X-ray-visible embolic microspheres were made from 10% Lipiodol-impregnated alginate using either electrostatic droplet generator (large embolics) or custom-made microfluidic devices (small embolics). Size uniformity was examined microscopically. The stability of these microspheres was assessed over two weeks in normal saline. In vitro biocompatibility was evaluated by examining the viability of encapsulated rabbit mesenchymal stem cells (rMSC) over time. X-ray visibility was determined in phantoms containing variable amount of the microspheres using C-arm CT.
Results: Highly uniform Lipiodol microspheres could be generated using either electrostatic droplet generator (274.8 ± 7.1 μm) or microfluidic device (51.5 ± 2.4μm) (Fig A, B). Both types of embolic particles remained stable as demonstrated by minimum size change over two weeks. The viability of rMSCs remained high for at least one week after encapsulation (89.8 ± 4.5%) (Fig C). Using a C-arm CT, Lipiodol beads could be readily detected in phantoms with a resolution of 2 particles (Fig D).
Conclusions: X-ray-visible Lipiodol microspheres can be custom generated within tight size tolerances and retain high biocompatibility to facilitate imaging-guided interventional procedures, such as BAE.
Author Disclosures: Y. Fu: None. C. Hu: None. C. Weiss: Research Grant; Significant; NIH/NIBIB R01 EB017615-01. H. Mao: None. C. Georgiades: None. D.L. Kraitchman: Research Grant; Significant; NIH/NIBIB R01 EB017615-01.
- © 2016 by American Heart Association, Inc.